

# The link between ceramide transporters, innate immunity and Alzheimer's disease

Citation for published version (APA):

Bode, G. H. (2016). The link between ceramide transporters, innate immunity and Alzheimer's disease. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20161014gb>

## Document status and date:

Published: 01/01/2016

## DOI:

[10.26481/dis.20161014gb](https://doi.org/10.26481/dis.20161014gb)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## SUMMARY

Alzheimer's disease (AD) is an enormous and increasing burden on society in many developed countries. Despite intense research efforts, there is still no effective cure. This indicates that we should direct more of our research effort to understanding the basic pathological processes of this disease and methods of drug delivery. It has recently emerged that sphingolipids, and in particular ceramides, are involved in the pathological processes of AD, but the exact mechanisms are currently unknown. The research described in this thesis is focused on two topics: The first topic is ceramide transporters and inflammation in neurodegenerative disease (Chapter 1-3), the second is nanoparticles for delivery of drugs to the brain (Chapters 4 and 5).

In **Chapter 1** we investigated the interaction between ceramide transporters (CERT) and Serum Amyloid P component (SAP). SAP is a non-fibrillar glycoprotein belonging to the pentraxin family of the innate immune system. We demonstrated that CERT specifically binds serum amyloid P (SAP) in its physiological conformations, pentamers and decamers. The START domain in CERT is important for this interaction. SAP and CERT form complexes in blood and partly colocalize in amyloid plaques from AD patients.

Additionally, we report a novel function of CERT/GPBP in complement activation in **Chapter 2**. Both CERT isoforms were found to bind the globularhead region of C1q and to initiate the classical complement pathway. In addition, C1q was shown to bind to endogenous CERT on the surface of apoptotic cells. These results demonstrate the involvement of CERTs in innate immunity, especially in the clearance of apoptotic cells.

In **Chapter 3** we used design-based stereology to quantify the number of CERT immunoreactive cells in the striatum of 6-hydroxydopamine (6-

## Summary

OHDA) lesioned rats as a model of Parkinson's disease (PD). No difference in the striatal expression levels of CERT/GPBP proteins was found between diseased and control animals, suggesting that the expression pattern of CERT in the striatum is not affected in the 6-OHDA rat model of PD.

**Chapter 4** describes development of an enzyme linked immunosorbent assay (ELISA) for the detection of peptides functionalized with biotin and fluorescein groups. We were able to accurately measure peptides bound to pentafluorophenyl methacrylate nanoparticles in blood plasma of rats after injection, with a detection limit of 1 ng/mL. This novel method is a valuable tool in determining the effectiveness of nanoparticle targeting.

In **Chapter 5** we evaluated the efficacy of delivery and safety of liposome-, polyester-, poly(glycidol)- and acrylamide-based nanoparticles functionalized with peptides targeting brain endothelial receptors, *in vitro* and *in vivo*. We detected labelled nanoparticles in brain homogenate, liver homogenate, in cerebrospinal fluid and blood plasma after injection. Based on both the *in vitro* and *in vivo* results, we concluded that the physical characteristics of the nanoparticles and the targeting peptides used need to allow for preferential binding to brain endothelial cells compared to endothelial cells of other tissues for efficient blood-brain barrier transport.